Oxford, UK - 27 August, 2020: Oxford Biomedica plc (LSE:OXB) ('Oxford Biomedica' or 'the Group'), a leading gene and cell therapy group, will be announcing its interim results for the six months ended 30 June 2020 on Thursday 17 September 2020.

A virtual briefing and Q&A session for analysts will be held at 13.00 BST / 08.00 EST on the day of results, and the presentation and webcast details will be made available on the Group's website at www.oxb.com. A replay webcast will be made available shortly afterwards.

-Ends-

Enquiries:
 Oxford Biomedica plc
 John Dawson, Chief Executive Officer, T: +44 (0)1865 783 000
Stuart Paynter, Chief Financial Officer, T: +44 (0)1865 783 000
Catherine Isted, Head of Corporate Development & IR, T: +44 (0)1865 954 161 / E: ir@oxb.com

Consilium Strategic Communications
 Mary-Jane Elliott / Matthew Neal, T: +44 (0)20 3709 5700

About Oxford Biomedica
 Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the 'Group') have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Santen, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally the group has signed a Clinical and Commercial Supply Agreement with AstraZeneca for manufacture of the adeno based COVID-19 vaccine candidate, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 550 peo

Attachments

  • Original document
  • Permalink

Disclaimer

Oxford BioMedica plc published this content on 27 August 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 August 2020 06:06:06 UTC